Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2002

View Archived Issues

Arena and Merck collaborate to develop drugs on GPCRs

Novel JNK inhibitors prepared and tested at Signal

AstraZeneca presents new CCR3 modulators with potential in asthma and allergic rhinitis

Potential use of two novel PDE4 inhibitors in allergic dermatitis

Potential use of theophylline in the management of functional chest pain

CDP-571 as a safe and effective option for Crohn's disease

Novel chelating agents with potential in the diagnosis and treatment of cancer

Novel group II mGluR agonists under study at Lilly

New C5a and/or IL-8 antagonists identified by Dompe researchers

GSK describes new IL-8 antagonists and their use in psoriasis, arthritis, etc.

New factor Xa inhibitors in early development at Morphochem

Novel analgesic alpha2B-adrenoceptor agonists in Allergan pipeline

Astex and Mitsubishi collaborate on metabolic drug discovery

Thai AIDSVAX trial cleared to continue

EHT-0201 enters phase II in ALS

IND filed for phase III trial of dexanabinol in traumatic brain injury

New glycylcycline antibiotic possesses excellent activity against rapidly growing mycobacteria

Novel gene therapy approach to the treatment of asthma based on IgE-binding protein

Chronic NCX-4016 attenuates development of atherosclerosis in mouse model

Immune modulation therapy protects rats against neuroinflammation

Combination of gene therapy + irradiation shows promise in prostate cancer model

U.S. and Korean researchers characterize vanilloid VR1 antagonists

New review on schizophrenia broadens the scope of Drug R&D Backgrounders

Clinical findings for HspE7 discussed at papillomavirus meeting

Entropin updates ENT-102 development progress

Metaglip approved for type 2 diabetes

Kineret sBLA submitted for inhibition of bone and joint damage due to RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...